Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vanderbilt University
Investor Deerfield Management and genomic sequencing giant Illumina entered into a five-year partnership to identify novel targets and drug candidates that may be spun out into new companies.
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Vanderbilt University Medical Center (VUMC)